India markets closed
  • BSE SENSEX

    49,591.32
    -154.88 (-0.31%)
     
  • Nifty 50

    14,834.85
    -38.95 (-0.26%)
     
  • USD/INR

    74.7190
    +0.1580 (+0.21%)
     
  • Dow

    33,800.60
    +297.00 (+0.89%)
     
  • Nasdaq

    13,900.19
    +70.89 (+0.51%)
     
  • BTC-INR

    4,476,240.00
    -22,158.50 (-0.49%)
     
  • CMC Crypto 200

    1,235.89
    +8.35 (+0.68%)
     
  • Hang Seng

    28,698.80
    -309.30 (-1.07%)
     
  • Nikkei

    29,768.06
    +59.06 (+0.20%)
     
  • EUR/INR

    88.9028
    +0.0430 (+0.05%)
     
  • GBP/INR

    102.3868
    -0.0112 (-0.01%)
     
  • AED/INR

    20.2980
    +0.0430 (+0.21%)
     
  • INR/JPY

    1.4647
    +0.0019 (+0.13%)
     
  • SGD/INR

    55.7130
    +0.0690 (+0.12%)
     

Indian vaccine giant SII warns of supply hit from U.S. raw materials export ban

·1-min read
FILE PHOTO: Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India poses for a picture at the Serum Institute of India, Pune

NEW DELHI (Reuters) - A temporary U.S. ban on exports of critical raw materials could limit the production of coronavirus vaccines by companies such as the Serum Institute of India (SII), its chief executive said in a World Bank panel discussion https://www.worldbank.org/en/events/2020/12/14/7th-south-asia-economic-policy-network-conference-on-vaccinating-south-asia on Thursday.

SII, the world's biggest vaccine maker, has licensed the AstraZeneca/Oxford University product and will soon start bulk-manufacturing the Novavax shot.

"There are a lot of bags, filters and critical items that manufacturers need," Adar Poonawalla said. "The Novavax vaccine, which we are a major manufacturer of, needs these items from the U.S."

He said the recent invocation of the U.S. Defence Production Act to preserve vaccine raw materials for its own companies went against the global goal of sharing vaccines equitably.

The White House said this week it had used the act to help drugmaker Merck & Co produce Johnson & Johnson’s COVID-19 vaccine.

"This really needs to be looked at because if they are talking about building capacity all over the world, the sharing of these critical raw materials, which just can't be replaced in a matter of six months or a year, is going to become a critical limiting factor," Poonawalla said.

India's Biological E has tied up with J&J to potentially contract manufacture up to 600 million doses of its vaccine per year. They have signed an initial deal but production volumes have not been agreed upon.

(Reporting by Krishna N. Das and Arghyadeep Dutta; editing by Jason Neely)